BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2021

View Archived Issues

Human cerebral organoids show utility to evaluate candidate inhibitors of prion accumulation in CJD

Read More

Phase III GOBI study of NOV-03 meets statistical significance on coprimary and secondary endpoints

Read More

BMC-128 shows promising antitumor activity in mouse model of melanoma

Read More

Phase II study of fostamatinib in patients with COVID-19 meets primary endpoint

Read More

FDA clears IND application for phase IIb study of AXA-1125 in NASH

Read More

Companies report progress of catumaxomab clinical trials for NMIBC

Read More

CFT-7455 shows potent tumor regression in IMiD-resistant multiple myeloma xenografts

Read More

First-in-class pan-inhibitor of KDM4 TACH-101 active in multiple cancer models

Read More

SPH Biotherapeutics presents new isolated antigen-binding proteins

Read More

New PARG inhibitors identified at Ideaya Biosciences

Read More

Accutar Biotechnology synthesizes new androgen receptor degrading PROTACs

Read More

Merck & Co. presents a novel potent, selective and brain-penetrant LRRK2 kinase inhibitor

Read More

Merck & Co. discovers KRAS G12C mutant inhibitors

Read More

BIAL Biotech discovers acid ceramidase inhibitors

Read More

BNT-162b2 and mRNA-1273 achieve only partial cross-neutralization of novel SARS-CoV-2 variants

Read More

Longeveron reports final phase I data on Lomecel-B in Alzheimer's disease

Read More

Development of human African trypanosomiasis carbazole drugs

Read More

New agonist MAb resolves chronic inflammation

Read More

New phase II trials evaluate BI-456906 in obesity and NASH

Read More

Tilt and MSD agree to study TILT-123 with Keytruda in ovarian cancer

Read More

Bispecific antibody targeting LAG-3 and PD-L1 (ABL501) for cancer immunotherapy

Read More

Iterion completes enrollment in phase I/IIa dose-expansion study of tegavivint in desmoid tumors

Read More

Moderna updates progress of COVID-19 vaccine program

Read More

Apellis reports 24-month data from phase Ib study of pegcetacoplan in geographic atrophy

Read More

Trodelvy gains accelerated approval in U.S. for advanced urothelial cancer

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing